Cingulate (CING) Free Cash Flow (2021 - 2025)
Cingulate's (CING) quarterly Free Cash Flow came in at -$3.8 million in Q4 2025, up 8.39% YoY from -$3.5 million in Q4 2024, and up 18.55% on a QoQ basis from -$4.6 million in Q1 2025.
Cingulate (CING) Free Cash Flow (2021 - 2025) Analysis & Trends
Cingulate (CING) has 5 years of Free Cash Flow data on file, last reported at -$3.8 million in Q4 2025.
- Quarterly Free Cash Flow rose 8.39% year-over-year to -$3.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$8.4 million (up 54.76% YoY) and the FY2025 annual result came in at -$17.4 million, up 5.82% from the prior year.
- Free Cash Flow rose to -$3.8 million in Q4 2025, from -$4.6 million in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of -$1.6 million in Q2 2021 to a low of -$8.8 million in Q1 2024.
- A 5-year average of -$3.8 million and a median of -$3.8 million in 2022 frame the typical range for Free Cash Flow.
- Annual changes were most pronounced in 2022 — Free Cash Flow slumped 180.46% — and 2024, when it jumped 59.14%.
- Tracing CING's Free Cash Flow over 5 years: stood at -$4.8 million in 2021, then gained by 9.34% to -$4.3 million in 2022, then soared by 36.79% to -$2.7 million in 2023, then slumped by 49.03% to -$4.1 million in 2024, then grew by 8.39% to -$3.8 million in 2025.
- The last three Free Cash Flow figures came in at -$3.8 million (Q4 2025), -$4.6 million (Q1 2025), and -$4.1 million (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -563.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 437.80 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 292.04 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 433.84 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -95.09 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 477.44 Mn |
| 10 | Cingulate | 72.85 Mn | 72.85 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -3.75 Mn |
| Dec 31, 2025 | -3.75 Mn |
| Mar 31, 2025 | -4.61 Mn |
| Mar 31, 2025 | -4.61 Mn |
| Dec 31, 2024 | -4.10 Mn |
| Dec 31, 2024 | -4.10 Mn |
| Sep 30, 2024 | -3.68 Mn |
| Sep 30, 2024 | -3.68 Mn |
| Jun 30, 2024 | -1.88 Mn |
| Jun 30, 2024 | -1.88 Mn |
| Mar 31, 2024 | -8.83 Mn |
| Mar 31, 2024 | -8.83 Mn |
| Dec 31, 2023 | -2.75 Mn |
| Dec 31, 2023 | -2.75 Mn |
| Sep 30, 2023 | -4.29 Mn |
| Sep 30, 2023 | -4.29 Mn |
| Jun 30, 2023 | -4.60 Mn |
| Jun 30, 2023 | -4.60 Mn |
| Mar 31, 2023 | -3.61 Mn |
| Mar 31, 2023 | -3.61 Mn |